Genesis Therapeutics Secures Equity Investment from NVIDIA’s NVentures to Advance AI-Driven Drug Discovery

Company Name: Genesis Therapeutics
Location: Burlingame, CA
Sector: AI-Driven Biotechnology

Funding Details:
Genesis Therapeutics, which specializes in using artificial intelligence for drug discovery, has received an equity investment from NVIDIA’s NVentures. While the exact amount remains undisclosed, this investment follows NVentures’ prior participation in the company’s $200 million Series B round in August 2023.

Purpose of Funding:
The funds will be used to further accelerate the development of Genesis’s AI platform, GEMS (Genesis Exploration of Molecular Space), which is integral to the company’s approach to drug discovery for complex molecular targets.

About Genesis Therapeutics:
Genesis Therapeutics utilizes its proprietary GEMS platform to streamline small molecule drug discovery. GEMS combines advanced AI technologies—such as language models, diffusion models, and physical machine learning simulations—to generate and optimize molecules for challenging biological targets. The platform supports the creation of innovative therapeutics by exploring extensive molecular possibilities efficiently and accurately.

Strategic Collaboration with NVIDIA:
Genesis is collaborating with NVIDIA to enhance the computational efficiency of GEMS, specifically optimizing neural network architectures that process 3D geometric data (protein and molecule structures). Key focus areas include advancing equivariant neural networks, which are crucial for accurate handling of molecular and structural data within drug discovery.

Leadership:

• CEO: Evan Feinberg, Ph.D., Founder

This collaboration between Genesis and NVIDIA underscores the role of AI in transforming molecular research, positioning Genesis to leverage NVIDIA's hardware and expertise to accelerate therapeutic innovation for complex diseases.